Cancer Treatment Today

Verzenio was initially s FDA approved in combination with fulvestrant to treat women with hormone receptor (HR)positive, human epidermal growth factor receptor 2 (HER2)negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), whose disease has progressed after hormonal therapy alone to treat adults with HRpositive, HER2negative advanced breast cancer or metastatic breast cancer whose disease has progressed after hormonal therapy and prior chemotherapy.FDA also approved Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced or metastatic breast cancer.

New evidence suggests that a CDK should be continued or switched to another CDK even after it failed. The approach appears to depend on recently reported date, such as, that Ribociclib extended PFS among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor, study results showed.

The findings of the double-blind, randomized phase 2 MAINTAIN trial, presented at ASCO Annual Meeting, demonstrated the potential benefit of continued CDK 4/6 inhibition with hormone therapy.
https://www.healio.com/news/hematology-oncology/20220606/continued-cdk-46-inhibition-after-breast-cancer-progression-may-benefit-some-patients, Accessed OCt 20, 2022

Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G, Iodice G, Nuzzo F, Pacilio C, Pensabene M, De Laurentiis M. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020 Sep 3;21(17):6400.

Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptorpositive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol. 2022;40(suppl 16):LBA1004. doi:10.1200/JCO.2022.40.16_suppl.LBA1004